Component,Publication Grant Number,Publication Doi,Publication Journal,Pubmed Id,Pubmed Url,Publication Title,Publication Year,Publication Keywords,Publication Authors,Publication Abstract,Publication Assay,Publication Tumor Type,Publication Tissue,Publication Dataset Alias,Publication Accessibility,PublicationView_id,Id,entityId
PublicationView,CA215845,10.1016/j.ccell.2020.12.014,Cancer Cell,33482121,https://pubmed.ncbi.nlm.nih.gov/33482121,Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities,2021,"Neuroendocrine, Emt, SCLC, Ascl1, Intratumoral Heterogeneity, Neurod1, Pou2f3","Carl M Gay, C Allison Stewart, Elizabeth M Park, Lixia Diao, Sarah M Groves, Simon Heeke, Barzin Y Nabet, Junya Fujimoto, Luisa M Solis, Wei Lu, Yuanxin Xi, Robert J Cardnell, Qi Wang, Giulia Fabbri, Kasey R Cargill, Natalie I Vokes, Kavya Ramkumar, Bingnan Zhang, Carminia M Della Corte, Paul Robson, Stephen G Swisher, Jack A Roth, Bonnie S Glisson, David S Shames, Ignacio I Wistuba, Jing Wang, Vito Quaranta, John Minna, John V Heymach, Lauren Averett Byers","Despite molecular and clinical heterogeneity, small cell lung cancer (SCLC) is treated as a single entity with predictably poor results. Using tumor expression data and non-negative matrix factorization, we identify four SCLC subtypes defined largely by differential expression of transcription factors ASCL1, NEUROD1, and POU2F3 or low expression of all three transcription factor signatures accompa(Read more on Pubmed)","Western Blotting, Flow Cytometry, Single Cell RNA-Sequencing",Lung Small Cell Carcinoma,Lung,"GSE151904, GSE138474",Open Access,33482121,aef2f0c6-9e87-40b2-8bdc-34405c0c9d0a,syn52543338
PublicationView,CA215845,10.3389/fonc.2020.01426,Front Oncol,32923395,https://pubmed.ncbi.nlm.nih.gov/32923395,Drug-Tolerant Idling Melanoma Cells Exhibit Theory-Predicted Metabolic Low-Low Phenotype,2020,"Melanoma, Metabolism, Drug tolerance, Idling, Low-Low","Dongya Jia, B Bishal Paudel, Corey E Hayford, Keisha N Hardeman, Herbert Levine, Jos√© N Onuchic, Vito Quaranta","Cancer cells adjust their metabolic profiles to evade treatment. Metabolic adaptation is complex and hence better understood by an integrated theoretical-experimental approach. Using a minimal kinetic model, we predicted a previously undescribed Low/Low (L/L) phenotype, characterized by low oxidative phosphorylation (OXPHOS) and low glycolysis. Here, we report that L/L metabolism is observed in <i(Read more on Pubmed)","Mathematical Modeling, RNA Sequencing",Melanoma,Skin,Not Appicable,Open Access,32923395,e98882b1-0914-48ff-b80d-53d817f50be1,syn52543338
PublicationView,CA215845,10.1101/gad.348295.121,Genes Dev,34016693,https://pubmed.ncbi.nlm.nih.gov/34016693,ASCL1 represses a SOX9<sup>+</sup> neural crest stem-like state in small cell lung cancer,2021,"Neuroendocrine, Lung cancer, Plasticity, small cell lung cancer, Mouse Models, SCLC, Ascl1, Cell Of Origin","Rachelle R Olsen, Abbie S Ireland, David W Kastner, Sarah M Groves, Kyle B Spainhower, Karine Pozo, Demetra P Kelenis, Christopher P Whitney, Matthew R Guthrie, Sarah J Wait, Danny Soltero, Benjamin L Witt, Vito Quaranta, Jane E Johnson, Trudy G Oliver","ASCL1 is a neuroendocrine lineage-specific oncogenic driver of small cell lung cancer (SCLC), highly expressed in a significant fraction of tumors. However, ‚àº25% of human SCLC are ASCL1-low and associated with low neuroendocrine fate and high MYC expression. Using genetically engineered mouse models (GEMMs), we show that alterations in <i>Rb1/Trp53/Myc</i> in the mouse lung induce an ASCL1<sup>+(Read more on Pubmed)","Cell Culture, Cell Proliferation Assay, Whole Exome Sequencing, Single Cell RNA-Sequencing, RNA Sequencing, Gene Ontology Enrichment Analysis, Mathematical Modeling",Lung Non-Small Cell Carcinoma,Lung,"GSE150084, PRJNA631050, PRJNA632351",Open Access,34016693,c305fd31-7e7e-461d-a7e9-2b64eb3cdf45,syn52543338
PublicationView,CA215845,10.3389/fnetp.2023.1225736,Front Netw Physiol,37731743,https://pubmed.ncbi.nlm.nih.gov/37731743,Quantifying cancer cell plasticity with gene regulatory networks and single-cell dynamics,2023,"Cancer, Plasticity, Dynamical Systems, Gene Regulatory Networks, Scrna-seq, Network Physiology","Sarah M Groves, Vito Quaranta","Phenotypic plasticity of cancer cells can lead to complex cell state dynamics during tumor progression and acquired resistance. Highly plastic stem-like states may be inherently drug-resistant. Moreover, cell state dynamics in response to therapy allow a tumor to evade treatment. In both scenarios, quantifying plasticity is essential for identifying high-plasticity states or elucidating transition(Read more on Pubmed)","Mathematical Modeling, Single Cell RNA-Sequencing",Pan-cancer,Not Applicable,Not Applicable,Open Access,37731743,8ad9b089-13b7-49ff-9cea-4b9c91645100,syn52543338
PublicationView,CA215845,10.1016/j.isci.2022.105224,iScience,36248730,https://pubmed.ncbi.nlm.nih.gov/36248730,Cooperative RNA degradation stabilizes intermediate epithelial-mesenchymal states and supports a phenotypic continuum,2022,"Mathematical Biosciences, Molecular Mechanism Of Gene Regulation","Benjamin Nordick, Mary Chae-Yeon Park, Vito Quaranta, Tian Hong","Multiple intermediate epithelial-mesenchymal transition (EMT) states reflecting hybrid epithelial and mesenchymal phenotypes were observed in physiological and pathological conditions. Previous theoretical models explaining multiple EMT states rely on regulatory loops involving transcriptional feedback, which produce three or four attractors. This is incompatible with the observed continuum-like E(Read more on Pubmed)","Mathematical Modeling, Single Cell RNA-Sequencing",Pan-cancer,"Lung, Breast","GSE147405, GSE213753",Open Access,36248730,96b3ac5f-ca1b-4307-bae8-09631f38c4d4,syn52543338
